Pharmacyclics Inc. (PCYC) and Servier announced after the bell Thursday that they have mutually and amicably ended their collaboration pertaining to the ex-U.S. development of Pharmacyclics' pan-HDAC inhibitor compounds involving abexinostat. Global development and commercialization rights will return to Pharmacyclics. The stock is now down 1.46 on 5K shares.
Pharmacyclics fell during the first hour of trade Thursday, but settled into a range for the remainder of the day. The stock closed down by 1.69 at $117.47 and closed testing the lower end of a 2-month range.
For comments and feedback contact: editorial@rttnews.com
Business News